No abstract

No abstract

No abstract

This study examines the supercritical carbon dioxide (SC-CO(2)) extraction of oryzanols contained rice bran oil from powdered rice bran. The extraction efficiencies and concentration factors of oryzanols, free fatty acids and triglycerides in the SC-CO(2) extracts were determined. With top-flow type SC-CO(2) extraction the total oil yield was 18.1% and the extraction efficiencies of oryzanols and triglycerides were 88.5 and 91.3% respectively, when 2750 g CO(2 )was consumed during the extraction of 35 g rice bran powder. The concentration factors of oryzanols and triglycerides in SC-CO(2)-extracted oil were higher than in the Soxhlet n-hexane extracted oil. SC-CO(2) extractions indicated that pressure can be used more effectively than temperature to enhance the extraction efficiency and concentration factor of oryzanols. A two-factor central composite scheme of response surface methodology was employed to determine the optimal pressure (300 bar) and temperature (313 K) for increasing the concentration of oryzanols in the SC-CO(2) extracted oil.

CDKN3 (cyclin-dependent kinase inhibitor 3), a dual specificity protein phosphatase, dephosphorylates cyclin-dependent kinases (CDKs) and thus functions as a key negative regulator of cell cycle progression. Deregulation or mutations of CDNK3 have been implicated in various cancers. However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown. Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis. Overexpression of CDKN3 sensitized the K562 leukemic cells to imanitib-induced apoptosis and dramatically inhibited K562 xenografted tumor growth in nude mouse model. Ectopic expression of CDKN3 significantly reduced the efficiency of Bcr-Abl-mediated transformation of FDCP1 cells to growth factor independence. In contrast, depletion of CDKN3 expression conferred resistance to imatinib-induced apoptosis in the leukemic cells and accelerated the growth of xenograph leukemia in mice. In addition, we found that CDKN3 mutant (CDKN3-C140S) devoid of the phosphatase activity failed to affect the K562 leukemic cell survival and xenografted tumor growth, suggesting that the phosphatase of CDKN3 was required for its tumor suppressor function. Furthermore, we observed that overexpression of CDKN3 reduced the leukemic cell survival by dephosphorylating CDK2, thereby inhibiting CDK2-dependent XIAP expression. Moreover, overexpression of CDKN3 delayed G1/S transition in K562 leukemic cells. Our results highlight the importance of CDKN3 in Bcr-Abl-mediated leukemogenesis, and provide new insights into diagnostics and therapeutics of the leukemia.